News headlines about Myriad Genetics (NASDAQ:MYGN) have been trending somewhat positive this week, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Myriad Genetics earned a news impact score of 0.17 on Accern’s scale. Accern also gave news coverage about the company an impact score of 45.7588364984841 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Here are some of the news articles that may have effected Accern’s rankings:

A number of equities research analysts have commented on MYGN shares. J P Morgan Chase & Co reaffirmed an “underweight” rating and issued a $16.00 target price on shares of Myriad Genetics in a research report on Friday, June 30th. Cowen and Company reissued a “hold” rating and set a $25.00 price objective on shares of Myriad Genetics in a research report on Friday, July 14th. Piper Jaffray Companies reissued a “hold” rating and set a $22.00 price objective on shares of Myriad Genetics in a research report on Friday, July 14th. Zacks Investment Research raised shares of Myriad Genetics from a “hold” rating to a “buy” rating and set a $28.00 price objective for the company in a research report on Monday, July 17th. Finally, BidaskClub downgraded shares of Myriad Genetics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 19th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and two have given a buy rating to the company’s stock. Myriad Genetics currently has a consensus rating of “Hold” and an average price target of $25.00.

Myriad Genetics (NASDAQ MYGN) opened at 36.10 on Tuesday. The company’s 50 day moving average is $33.89 and its 200-day moving average is $25.65. The stock has a market cap of $2.47 billion, a PE ratio of 113.17 and a beta of 0.27. Myriad Genetics has a 1-year low of $15.15 and a 1-year high of $37.30.

Myriad Genetics (NASDAQ:MYGN) last released its quarterly earnings results on Tuesday, August 8th. The company reported $0.30 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.26 by $0.04. The company had revenue of $200.50 million for the quarter, compared to analyst estimates of $193.71 million. Myriad Genetics had a net margin of 6.33% and a return on equity of 6.73%. The firm’s revenue was up 7.5% on a year-over-year basis. During the same quarter last year, the business earned $0.36 earnings per share. Equities research analysts forecast that Myriad Genetics will post $1.03 earnings per share for the current fiscal year.

In other news, Director John T. Henderson sold 30,000 shares of Myriad Genetics stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $30.30, for a total value of $909,000.00. Following the sale, the director now owns 52,524 shares in the company, valued at $1,591,477.20. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 6.70% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY NOTICE: “Myriad Genetics (MYGN) Getting Somewhat Positive News Coverage, Report Finds” was originally published by Daily Political and is owned by of Daily Political. If you are accessing this report on another website, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The correct version of this report can be accessed at

About Myriad Genetics

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Insider Buying and Selling by Quarter for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with's FREE daily email newsletter.